Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 7/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443176 | 1.00 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2RAB9AACEREN | |
| SCHEMBL26691320 | 0.83 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2RAB9AACEREN | |
| SCHEMBL202763 | 0.83 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2RAB9AACEREN | |
| SCHEMBL202764 | 0.83 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2RAB9AACEREN | |
| Hydrochloric Acid SCHEMBL3924876 | 0.82 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2RAB9AACEREN | |
| SCHEMBL3349893 | 0.81 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2RAB9AACEREN | |
| SCHEMBL3349891 | 0.81 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2RAB9AACEREN | |
| SCHEMBL28784343 | 0.79 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2RAB9AACE | |
| SCHEMBL30353922 | 0.78 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2RAB9AACEREN | |
| SCHEMBL27682627 | 0.76 | RAB9A (0.41) | ALDH1A1SMN1; SMN2RAB9AACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230104758-A1 | COMPOUNDS AND METHODS FOR AMINE OXIDASE IMAGING | ETH ZURICH (CH) | 2023-04-06 | — | — | US | disclosed |
| EP-4069684-A2 | COMPOUNDS AND METHODS FOR AMINE OXIDASE IMAGING | ETH Zurich (CH) | 2022-10-12 | — | — | EP | disclosed |
| WO-2021110834-A2 | COMPOUNDS AND METHODS FOR AMINE OXIDASE IMAGING | ETH ZURICH (CH) | 2021-06-10 | — | — | WO | disclosed |
| EP-3831820-A1 | COMPOUNDS AND METHODS FOR AMINE OXIDASE IMAGING | ETH Zurich (CH) | 2021-06-09 | — | — | EP | disclosed |
| US-9175038-B2 | Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2015-11-03 | — | — | US | disclosed |
| US-20120065146-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2010132869-A2 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | GOVERNMENT OF THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230104758-A1 | COMPOUNDS AND METHODS FOR AMINE OXIDASE IMAGING | DAO, LOX, AOC2 | ALDH1A1 91/4885SMN1; SMN2 2849/4885RAB9A 3553/4885 |
| US-20120065146-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PLK2, PLK4 | ALDH1A1 4782/4885SMN1; SMN2 3879/4885RAB9A 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.